drugset / Trial / NCT00605553
Study to Evaluate SYN115 in Parkinson's Disease
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is an exploratory study to evaluate if SYN115 has an effect on Parkinson's disease as measured by clinical symptoms and brain images using magnetic resonance imaging (MRI) when a function test is administered.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-05
- Completion
- 2009-05
Publications
- Results Black KJ, Campbell MC, Dickerson W, Creech ML, Koller JM, Chung SC, Bandak SI: A randomized, double-blind, placebo-controlled cross-over trial of the adenosine 2a antagonist SYN115 in Parkinson disease. Neurology 74(9): A317, 2010.
- Results Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci. 2010 Dec 1;30(48):16284-92. doi: 10.1523/JNEUROSCI.2590-10.2010.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozadenant | Small molecule | 20 mg | Oral |
| Subject | Tozadenant | Small molecule | 60 mg | Oral |